Metabolize
PrivateLast Round
Seed
Oct 15, 2026
Total Funding Raised
$3.2M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Metabolize is a consumer health company that develops metabolic health products based on proprietary Precision Metabolite™ Technology licensed from Stanford Medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, D2C Brands, Subscription Commerce, Sports & Fitness
Business Model
B2C
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Metabolize Comparables
Compare Metabolize with similar companies based on industry and business-model similarity.
Metabolize Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 15, 2026 |
Metabolize Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Seed |
| Astanor Ventures | Seed |
| Maia Ventures | Seed |
| SOSV | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2026
$3.2M round led by Astanor Ventures
- Sep 12, 2026
Monthly visitors grew 1320% MoM, reaching 1.8K.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
Metabolize develops Precision Metabolite(TM) Technology under an exclusive license to Stanford-originated intellectual property, translating patent-protected discoveries into consumer metabolic health products designed to work with the body's natural biology, as announced in California on Oct 15th '26.
- launchesOct 15, 2026
Metabolize's first consumer product, NATLEAN, is expected to launch in Jan '27 to help people transitioning off GLP-1 therapies reduce food noise, regulate appetite and support long-term weight management.
- receives_financingOct 15, 2026
Metabolize receives $3.2M in Seed financing led by Astanor, with participation from Maia Ventures, LongGame Venture and SOSV, on Oct 15th '26 in California to accelerate commercialization of its Precision Metabolite(TM) Technology and support metabolic health product development.
Metabolize Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Metabolize's valuation, stock price, and market status.
Is Metabolize a public or private company?
Metabolize is a private company.
What is the current stock price of Metabolize?
Metabolize is a private company, so its shares have no public market price. Caplight tracks Metabolize's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Metabolize worth (valuation)?
Valuation information for Metabolize is not publicly available.
Can I buy Metabolize stock?
Metabolize shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Metabolize's last funding round?
Metabolize's most recent funding round was Seed on October 15, 2026.
Who are the main investors in Metabolize?
Key investors in Metabolize include Astanor Ventures.
Will Metabolize IPO soon?
No public IPO plans have been announced for Metabolize.
How can I track Metabolize secondary market activity?
Caplight tracks bids, offers, and trades in Metabolize's shares on secondary markets.